17th Annual Scientific Meeting – Virtual Edition
06 – 09 April, 2021 // Virtual Conference
Distinguished Poster Award Recipient:
|
|||
| Facial and vocal markers of schizophrenia measured using remote smartphone assessments (Koesmahargyo) | |||
|
View all Poster PDFs and Abstracts |
|||
6 April 2021 |
|||
| Welcome from the President | Ramy Mahmoud slides video |
||
| Novel clinical trial designs: Can we define CNS clinical trial inclusion criteria and outcomes based on RDoC circuits and mechanisms? | Chairs: Uma Vaidyanathan Andrew Krystal |
||
| Research Domain Criteria (RDoC) initiative: An overview | Uma Vaidyanathan slides video |
||
| Fast-Fail Trials in mood and anxiety spectrum disorders: Using brain biomarkers vs diagnoses for improving CNS trial design | Andrew Krystal slides video |
||
| Psychiatric Ratings using Intermediate Stratified Markers (PRISM): Transdiagnostic markers for social dysfunction across schizophrenia and Alzheimer’s disease as outcome measures | Martien Kas slides video |
||
| Moving towards a new psychiatry: Targeting patient subtypes and symptom domains | Giacomo Salvadore Wayne Drevets slides video |
||
| Stratifying a dimensional psychosis population for CNS trials using results from B-SNIP Network | Carol Tamminga slides video |
||
| From intentions to applications: An industry perspective on RDoC inspired drug development | Vikas Mohan Sharma slides video |
||
| Challenges in moving to a circuit/mechanism-based approach such as RDoC from FDA and EMA perspectives | Michael Davis slides video Lorenzo Guizzaro slides video |
||
| Panel/Regulatory Discussion | video |
||
|
Poster Session |
Poster PDFs and Abstracts | ||
| New Investigator Awardees – Poster Presentations | Awardees noted * in above list | ||
7 April 2021 |
|||
| Wednesday Working Group Sessions | |||
| Assessment methods and endpoints for Rapid-Acting Antidepressants – RAADs | Chairs: Elizabeth Ballard Mark Opler Christian Yavorsky |
||
| Estimands and missing data | Chairs: Elena Polverejan Pilar Lim summary |
||
| ISCTM/ECNP joint COVID-19 CNS clinical methodologies blueprint | Chairs: Kemi Olugemo Dragana Bugarski-Kirola Gerard Dawson summary |
||
| Approaches to multimodal therapies: From psychedelics to neuromodulation – Psychedelics | Chairs: Walter Dunn Stephen Marder |
||
| Welcome | Stephen Marder slides video |
||
| Integrating multiple therapeutic modalities framework and design challenges | Nina Schooler slides video |
||
| Integrated therapeutics: Rationale and unresolved questions | Gerard Sanacora slides video |
||
| Seven controversies in psychedelic medicine | Alexander Belser slides video |
||
| FDA: Regulatory perspectives on psychedelic-based integrated therapeutics | Javier Muniz slides video |
||
| EMA: Regulatory considerations on integrated therapeutics: Design features and other regulatory considerations | Lorenzo Guizzaro slides video |
||
| Panel/Regulatory Discussion | video
|
||
8 April 2021 |
|||
| Inaugural Lewis Alan Opler Prize Presentation | Carla Canuso Mark Opler slidesAlex Cohen slides video |
||
| Approaches to multimodal therapies: From psychedelics to neuromodulation – Neuromodulation | Chairs: Walter Dunn Stephen Marder |
||
| Introduction | Walter Dunn slides video |
||
| Integrating cognitive interventions with neuromodulation | Sarah Lisanby slides video |
||
| Current and future studies of neuromodulation combined with other health interventions | Jeff Daskalakis slides video |
||
| Studies integrating neurocognitive, social cognitive, or functional skills training with medication | Michael Sand slides video |
||
| Fostering innovative digital health technologies: An FDA digital health center of excellence perspective | Ian Marcus slides video |
||
| FDA psychiatric device pipeline and regulations: A staff perspective | Anita Bajaj slides video |
||
| Discussion | video
|
||
| EMA Regulatory perspectives on multimodal therapies: Neuromodulation | Florence Butlen-Ducuing slides video |
||
| Panel / Audience Discussion | video |
||
|
Thursday Working Group Sessions |
|||
| Algorithms/Flags to identify clinical inconsistency in the use of rating scales in CNS RCTs | Chairs: Jonathan Rabinowitz Nina Schooler summary |
||
| Innovative technologies for CNS clinical trials | Chairs: Richard Keefe Michael Davis |
||
| Negative symptoms: Remote trial design methodologies | Chairs: Stephen Marder David Daniel summary |
||
| Orphan diseases | Chairs: Joan Busner Gahan Pandina summary |
||
9 April 2021
|
|||
| Andrew C. Leon Distinguished Career Award Presentation | Ramy Mahmoud Carla Canuso slidesStephen Marder slides video |
||
|
Issues and strategies regarding polypharmacy in clinical trials |
Chairs: Mark Weiser Philip Harvey |
||
| Introduction | Philip Harvey slides video |
||
| Antipsychotic polypharmacy in schizophrenia | Mark Weiser slides video |
||
| Statistical issues in clinical trials with polypharmacy | Jonathan Rabinowitz slides video |
||
| Discussion | video
|
||
| Polypharmacy in people with HIV: Effects on the brain | Scott Letendre slides video |
||
| Issues and strategies regarding polypharmacy in clinical trials: Bipolar Disorder | Andrew Nierenberg slides video |
||
| Hypertension treatment and trials as model polypharmacy | Franz Messerli slides video |
||
| Panel / Regulatory Discussion | Facilitator: Stephen Brannan All Speakers and Panelist: Florence Butlen-Ducuing video |
||
| Meeting Adjourned
|
Ramy Mahmoud slides video |
||